[{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pivmecillinam","moa":"PBP1A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"UTILITY therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UTILITY therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UTILITY therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pivmecillinam","moa":"PBP1A","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"UTILITY therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UTILITY therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UTILITY therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Pivmecillinam","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"UTILITY therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UTILITY therapeutics \/ AMR Action Fund","highestDevelopmentStatusID":"12","companyTruncated":"UTILITY therapeutics \/ AMR Action Fund"},{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Pivmecillinam","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"UTILITY therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UTILITY therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UTILITY therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Pivmecillinam Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

BioAsia
Not Confirmed
BioAsia
Not Confirmed

Details : Pivya (pivmecillinam) oral tablets are FDA-approved for uncomplicated UTIs in adult females caused by susceptible E. coli, Proteus mirabilis, and Staphylococcus saprophyticus.

Product Name : Pivya

Product Type : Small molecule

Upfront Cash : Not Applicable

April 24, 2024

Lead Product(s) : Pivmecillinam

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

BioAsia
Not Confirmed
BioAsia
Not Confirmed

Details : Proceeds develop and commercialize European-approved antibiotics Pivya (pivmecillinam), an oral prodrug of mecillinam, and mecillinam, an intravenous (IV) formulation for UTIs.

Product Name : Pivya

Product Type : Small molecule

Upfront Cash : Undisclosed

January 17, 2024

Lead Product(s) : Pivmecillinam

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : AMR Action Fund

Deal Size : Undisclosed

Deal Type : Financing

blank

03

BioAsia
Not Confirmed
BioAsia
Not Confirmed

Details : Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI), and it has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended spectrum beta-lactamases.

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Not Applicable

September 29, 2021

Lead Product(s) : Pivmecillinam

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

BioAsia
Not Confirmed
BioAsia
Not Confirmed

Details : Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI), and it has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended-spectrum beta-lactamases.

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Not Applicable

June 15, 2021

Lead Product(s) : Pivmecillinam

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank